Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as part of its ongoing evaluation of Leqembi (lecanemab), which was turned ...
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...
Two bills aim to close gaps and ensure equitable access by requiring private health insurance coverage of FDA-approved Alzheimer’s treatments.
The Therapeutic Goods Administration (TGA) of Australia has declined the approval of Leqembi (lecanemab) as a treatment for ...
Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback